Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2022; 11(02): 175-177
DOI: 10.1055/s-0041-1739178
Case report

Secondary Acute Myeloid Leukemia in a Chronic Myeloid Leukemia Patient in Deep Molecular Response—An Unusual Case Report

Goranthala Bharathi Devi
1   Department of Medical Oncology, Cancer Institute (WIA), Adyar, Chennai, Tamil Nadu, India
,
Perumal Kalaiyarasi Jayachandran 
1   Department of Medical Oncology, Cancer Institute (WIA), Adyar, Chennai, Tamil Nadu, India
,
Jhansi Rani Arumugam
2   Department of Hematopathology, Cancer Institute (WIA), Adyar, Chennai, Tamil Nadu, India
,
Karthik Bommannan
2   Department of Hematopathology, Cancer Institute (WIA), Adyar, Chennai, Tamil Nadu, India
,
Shirley Sundersingh
2   Department of Hematopathology, Cancer Institute (WIA), Adyar, Chennai, Tamil Nadu, India
› Author Affiliations Funding There were no external sources of funding for this project.
› Further Information
   Permissions and Reprints

Abstract

Zoom Image
Perumal Kalaiyarasi Jayachandran

Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder that develops from the stem cell compartment. The classical translocation (BCR-ABL1) is present in approximately 95% of CML patients. Through disease progression, clonal evolution with additional chromosomal abnormalities (ACAs) start appearing. Although relatively rare, chromosomal abnormalities can exist or develop in the Philadelphia (Ph)-negative clones, which may lead to the evolution of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). We hereby present a case of AML which emerged from a Ph-negative clone in a patient with a history of CML who was in deep molecular response. The possible mechanisms of ACAs have been discussed.

Keywords

AML in CML - secondary AML - additional chromosomal abnormalities in Ph-negative clone - clonal evolution - secondary clone


Publication History

Article published online:
22 March 2022

© 2022. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Champlin RE, Golde DW. Chronic myelogenous leukemia: recent advances. Blood 1985; 65 (05) 1039-1047
    CrossrefPubMedGoogle Scholar
  • 2 Baccarani M, Deininger MW, Rosti G. et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013; 122 (06) 872-884
    CrossrefPubMedGoogle Scholar
  • 3 Jabbour E, Kantarjian HM, Abruzzo LV. et al. Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 2007; 110 (08) 2991-2995
    CrossrefPubMedGoogle Scholar
  • 4 Wang X, Zeng L, Wang J. et al. A positive role for c-Abl in Atm and Atr activation in DNA damage response. Cell Death Differ 2011; 18 (01) 5-15
    CrossrefPubMedGoogle Scholar
  • 5 Bumm T, Müller C, Al-Ali H-K. et al. Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 2003; 101 (05) 1941-1949
    CrossrefPubMedGoogle Scholar
  • 6 Terre C, Eclache V, Rousselot P. et al; France Intergroupe pour la Leucemie Myeloide Chronique. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia 2004; 18 (08) 1340-1346
    CrossrefPubMedGoogle Scholar
  • 7 Kovitz C, Kantarjian H, Garcia-Manero G, Abruzzo LV, Cortes J. Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. Blood 2006; 108 (08) 2811-2813
    CrossrefPubMedGoogle Scholar
  • 8 Schmidt M, Rinke J, Schäfer V. et al. Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status. Leukemia 2014; 28 (12) 2292-2299
    CrossrefPubMedGoogle Scholar
  • 9 Deininger MWN, Cortes J, Paquette R. et al. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells. Cancer 2007; 110 (07) 1509-1519
    CrossrefPubMedGoogle Scholar
  • 10 Bhatia R, McGlave PB, Dewald GW, Blazar BR, Verfaillie CM. Abnormal function of the bone marrow microenvironment in chronic myelogenous leukemia: role of malignant stromal macrophages. Blood 1995; 85 (12) 3636-3645
    CrossrefPubMedGoogle Scholar